Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Heart transplantation in patients from socioeconomically distressed communities.
Chen Q, Malas J, Emerson D, Megna D, Catarino P, Esmailian F, Chikwe J, Czer LS, Kobashigawa JA, Bowdish ME. Chen Q, et al. Among authors: bowdish me. J Heart Lung Transplant. 2024 Feb;43(2):324-333. doi: 10.1016/j.healun.2023.08.004. Epub 2023 Aug 15. J Heart Lung Transplant. 2024. PMID: 37591456
When a Patient Dies: How I Teach It.
Cohen RG, Bowdish ME. Cohen RG, et al. Among authors: bowdish me. Ann Thorac Surg. 2017 Oct;104(4):1108-1110. doi: 10.1016/j.athoracsur.2017.06.008. Ann Thorac Surg. 2017. PMID: 28935296 Review. No abstract available.
Ventricular tachycardia in the era of ventricular assist devices.
Cesario DA, Saxon LA, Cao MK, Bowdish M, Cunningham M. Cesario DA, et al. J Cardiovasc Electrophysiol. 2011 Mar;22(3):359-63. doi: 10.1111/j.1540-8167.2010.01911.x. Epub 2010 Oct 19. J Cardiovasc Electrophysiol. 2011. PMID: 20958827 Review.
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Lancet Infect Dis. 2022 May;22(5):622-635. doi: 10.1016/S1473-3099(21)00751-9. Epub 2021 Dec 23. Lancet Infect Dis. 2022. PMID: 34953520 Free PMC article. Clinical Trial.
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial.
Temesgen Z, Kelley CF, Cerasoli F, Kilcoyne A, Chappell D, Durrant C, Ahmed O, Chappell G, Catterson V, Polk C, Badley A, Marconi VC; LIVE-AIR Study Group. Temesgen Z, et al. Thorax. 2023 Jun;78(6):606-616. doi: 10.1136/thoraxjnl-2022-218744. Epub 2022 Jul 6. Thorax. 2023. PMID: 35793833 Free PMC article. Clinical Trial.
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.
Temesgen Z, Burger CD, Baker J, Polk C, Libertin CR, Kelley CF, Marconi VC, Orenstein R, Catterson VM, Aronstein WS, Durrant C, Chappell D, Ahmed O, Chappell G, Badley AD; LIVE-AIR Study Group. Temesgen Z, et al. Lancet Respir Med. 2022 Mar;10(3):237-246. doi: 10.1016/S2213-2600(21)00494-X. Epub 2021 Dec 1. Lancet Respir Med. 2022. PMID: 34863332 Free PMC article. Clinical Trial.
138 results